{"": [135, 144, 0, 145, 1302, 0], "Introduction": [1303, 4615, 0], "Cells and monoclonal antibody": [4632, 5261, 0], "VSV-SARS-CoV-2 mutants": [5262, 6906, 0], "Tc bovines": [6907, 7624, 0], "Generation of pCAGGS and Spike fusion protein for Tc Bovine immunization": [7625, 10272, 0], "Tc bovine immunization and plasma collection": [10273, 11149, 0], "SAB-185 cGMP purification": [11150, 12831, 0], "SARS CoV-2 spike-protein-specific human IgG ELISA": [12832, 14130, 0], "Plaque reduction neutralization assay and plaque assay": [14131, 16006, 0], "Neutralization assays using a recombinant VSV-SARS-CoV-2 and mutants": [16007, 17049, 0], "Method details": [4616, 17049, 1], "Production of polyclonal human IgG against SARS-CoV-2 spike in transchromosomic bovines": [17059, 18185, 0], "Effect of Tc-hIgG-SARS-CoV-2 on neutralization of SARS-CoV-2": [18186, 20141, 0], "Selections for resistance mutations using chimeric VSV-SARS-CoV-2": [20142, 20827, 0], "Results": [17050, 20827, 1], "Discussion": [20828, 23876, 0], "Limitations of this study": [23877, 24015, 0]}